Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson
University of California at San Francisco, San, Francisco, CA 94143, USA
J Clin Oncol 21:976-83. 2003
..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
- Can we abandon anthracyclines for early breast cancer patients?
I Craig Henderson
Department of Medicine, University of California at San Francisco, USA
Oncology (Williston Park) 25:115-24, 127. 2011
..The results of these studies are provocative but insufficient to justify the conclusion that anthracyclines can be either abandoned or used only for a very select group of patients...
- Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
I Craig Henderson
Adjunct Professor of Medicine, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA
Expert Rev Anticancer Ther 7:919-43. 2007
..Although it is not yet clear whether nab-paclitaxel can be routinely substituted for CrEL-paclitaxel or docetaxel in breast cancer treatment regimens, it seems highly likely that this will occur within the next 5 years...
- Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer
Beth Overmoyer
Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 5055, USA
Clin Breast Cancer 6:150-7. 2005
..Pegylated liposomal doxorubicin (PLD) is an active agent for breast cancer. The efficacy and safety of PLD in combination with cyclophosphamide as first-line treatment of metastatic breast cancer (MBC) was evaluated in this phase II study...
- Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants
Elizabeth B Lamont
Department of Medicine and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA 02114, USA
J Natl Cancer Inst 97:1080-3. 2005
..Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer...
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry
University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
JAMA 295:1658-67. 2006
..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
- Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)
Elizabeth B Lamont
Massachusetts General Hospital Cancer Center and Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA
J Natl Cancer Inst 98:1335-8. 2006
....
- Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
Hyman B Muss
University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
J Clin Oncol 25:3699-704. 2007
..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
- HER2 and response to paclitaxel in node-positive breast cancer
Daniel F Hayes
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
N Engl J Med 357:1496-506. 2007
..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
Minetta C Liu
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
Cancer Treat Rev 34:223-30. 2008
..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participantsElizabeth B Lamont
Massachusetts General Hospital, Boston, Massachusetts, USA
Med Care 46:303-8. 2008
..Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly...
- Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
Michael P Digiovanna
Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
J Clin Oncol 26:2364-72. 2008
....
- Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
Lynn G Dressler
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
J Clin Oncol 23:4287-97. 2005
....
- Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial
Jennifer R Bellon
Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
J Clin Oncol 23:1934-40. 2005
..The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question...
- Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
Hyman B Muss
Fletcher Allen Health Care, Vermont Cancer Center, Burlington, VT 05401, USA
JAMA 293:1073-81. 2005
....
- High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry
Donald A Berry
University of Texas M D Anderson Cancer Center, Houston, 77030, USA
J Clin Oncol 20:743-50. 2002
..To assess survival of patients with metastatic breast cancer treated with high-dose chemotherapy (HDC) versus standard-dose chemotherapy (SDC)...
- Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B
Raymond B Weiss
Walter Reed Army Medical Center, Washington, DC, USA
J Clin Oncol 21:1825-35. 2003
....
- Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
Eric P Winer
Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
J Clin Oncol 22:2061-8. 2004
..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
- Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
Alan M Keller
US Oncology Inc, Cancer Care Associates, 6151 S Yale, Tulsa, OK 74136, USA
J Clin Oncol 22:3893-901. 2004
..To compare the efficacy of pegylated liposomal doxorubicin (PLD) with that of a common salvage regimen (comparator) in patients with taxane-refractory advanced breast cancer...
- Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344
Carolyn I Sartor
Dept of Radiation Oncology, University of North Carolina School of Medicine, CB7512, Chapel Hill, NC 27599, USA
J Clin Oncol 23:30-40. 2005
....
- The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
Nicholas J Robert
The Cancer Center, Inova Fairfax Hospital, Falls Church, VA, USA
Semin Oncol 31:106-46. 2004
..The toxicity profile of NPLD is similar to that of conventional doxorubicin, but toxicities are less severe and NPLD is better tolerated than conventional doxorubicin at higher doses...
- Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
Anthony J Guidi
North Shore Medical Center, Salem, MA, USA
J Clin Oncol 20:732-42. 2002
....
- Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective
Anjali S Kumar
University of California, 1600 Divisadero Street, San Francisco, CA 94115, USA
Breast Cancer Res 7:271-5. 2005
..Treatment of DCIS with tamoxifen is still limited...
- Axillary surgery: clinical judgment required
I Craig Henderson
J Clin Oncol 24:325-6. 2006
- Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
Kevin S Hughes
Avon Comprehensive Breast Evaluation Center, Breast Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA
N Engl J Med 351:971-7. 2004
..In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy...
- The evolving role of aromatase inhibitors in adjuvant breast cancer therapy
I Craig Henderson
Carol Franc Buck Breast Care Center, University of California San Francisco Comprehensive Cancer Center, 94143, USA
Clin Breast Cancer 6:206-15. 2005
..In addition, case-based discussions are included to provide direction on how to integrate recent endocrine adjuvant clinical trial findings into everyday practice...
- Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
Robert W Carlson
Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003
....
- A rose is no longer a rose
I Craig Henderson
J Clin Oncol 20:3365-8. 2002
- Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit
I Craig Henderson
University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA 94123, USA
Semin Oncol 31:31-4. 2004
....
